KDR and Hepatic fibrosis: In a recent study, researchers explored a vascular-targeted therapy for liver fibrosis by using the adeno-associated viral vector serotype 9 (AAV9) with a short hairpin RNA (shRNA) of LECT2 combined with recombinant VEGF (rVEGF, VEGF/VEGFR signaling activator) or bevacizumab (VEGF neutralizing antibody, VEGF/VEGFR signaling inhibitor) to simultaneously regulate hepatic endothelial cells in different zonations (134).